Metabolic and Molecular Mechanisms of NAFLD/NASH

摘要 请求为题为《代谢和分子机制》的Keystone专题讨论会提供支助 NAFLD/NASH，由詹姆斯·特雷瓦斯基博士、Jacquelyn Maher博士和Quentin Anstee博士组织。这次会议 将于2023年3月19日至23日在加拿大艾伯塔省班夫举行。 非酒精性脂肪性肝病(NAFLD)和脂肪性肝炎(NASH)代表 代谢综合征，并正在成为发病率和死亡率的关键驱动因素，特别是在 严重肝纤维化的背景。NASH的组织学特征包括脂肪变性、小叶 炎症和肝细胞气球膨胀是很好的特征；然而，尽管人们普遍认为 NASH是一种进行性疾病，是启动和推动NASH的致病和分子机制 在很大程度上仍然不为人知。因此，这次会议的目的是将广泛的科学团体聚集在一起 和临床研究人员强调和讨论目前探索关键生物学过程的证据 与NASH和肝纤维化有关。这次会议的主题包括胰岛素抵抗， 脂肪变性和非酒精性肝病背景下的肝细胞脂质管理/脂毒性和炎症。此外， NAFLD/NASH的分子和遗传调控及其进展 对肝纤维化的防治也将受到重视。最后，由于NASH是一个未得到满足的医疗需求，该计划将整合 早期的基础生物学讨论和治疗剂的临床进展的最新进展，以及 联合用药，用于治疗NASH和肝纤维化。最后，本次大会将联合召开 与纤维化的发病机制和解决：从机制到治疗。联席会议将集中讨论 肝以外器官纤维化的关键细胞驱动因素和媒介允许跨功能 对纤维性疾病的病理生物学有更深入的认识和讨论。来自两个会议的与会者 将有机会通过共享会议、用餐时间和晚上海报会议来建立网络。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Metabolic and Molecular Mechanisms of NAFLD/NASH, organized by Drs. James Trevaskis, Jacquelyn Maher and Quentin Anstee. The conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023. Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) represents the hepatic manifestation of the metabolic syndrome and is emerging as a key driver of morbidity and mortality, particularly when present in the context of severe liver fibrosis. The histological hallmarks of NASH including steatosis, lobular inflammation and hepatocyte ballooning are well-characterized; however, while it is widely recognized that NASH is a progressive disease, the pathogenic and molecular mechanisms that initiate and drive NASH remain largely unknown. Therefore, this conference was designed to bring together a broad group of scientific and clinical researchers to highlight and discuss the current evidence exploring the key biological processes involved in NASH and liver fibrosis. This conference program will cover topics such as insulin resistance, hepatocyte lipid management/lipotoxicity and inflammation in the context of steatosis and NASH. Furthermore, advances in our understanding of the molecular and genetic regulation of NAFLD/NASH and the progression to liver fibrosis will also be highlighted. Finally, as NASH is an unmet medical need, this program will integrate the earlier fundamental biology discussion with updates on clinical progress of therapeutic agents, and combinations of agents, for the treatment of NASH and liver fibrosis. Finally, this conference will be held jointly with Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies. The joint conference will focus on the key cellular drivers and mediators of fibrosis in organs beyond the liver and allows for cross-functional discussion and deeper understanding of pathobiology of fibrotic disease. Participants from both conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster sessions.